Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia

Pathologic myopia is the second cause of choroidal neovascularization, after age-related macular degeneration (AMD), and the first cause in patients younger than 50 years. The current treatment of subfoveal myopic choroidal neovascularization (mCNV) is verteporfin photodynamic therapy, but its long-...

Full description

Bibliographic Details

Published in:	Retina (Philadelphia, Pa.) Vol. 29; no. 8; p. 1062
Main Author:	Cohen, Salomon Y
Format:	Journal Article
Language:	English
Published:	United States 01.09.2009
Subjects:	Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - adverse effects Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized Bevacizumab Choroidal Neovascularization - drug therapy Choroidal Neovascularization - etiology Humans Myopia, Degenerative - complications Myopia, Degenerative - drug therapy Ranibizumab Treatment Outcome Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - drug effects
ISSN:	1539-2864, 1539-2864
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!